OU Researcher to Study CAR T-Cell and Opaganib Combination in Clinical Trials for Ultra-High-Risk Multiple Myeloma
October 20, 2026
October 20, 2026
OKLAHOMA CITY, Oklahoma, Oct. 20 -- The University of Oklahoma Health campus issued the following news:
* * *
OU Researcher to Study CAR T-Cell and Opaganib Combination in Clinical Trials for Ultra-High-Risk Multiple Myeloma
October 19, 2026
University to Manufacture CAR T Cells on Campus
-
OKLAHOMA CITY - Patients with ultra-high-risk multiple myeloma, an aggressive form of blood cancer, often respond poorly to standa . . .
* * *
OU Researcher to Study CAR T-Cell and Opaganib Combination in Clinical Trials for Ultra-High-Risk Multiple Myeloma
October 19, 2026
University to Manufacture CAR T Cells on Campus
-
OKLAHOMA CITY - Patients with ultra-high-risk multiple myeloma, an aggressive form of blood cancer, often respond poorly to standa . . .